21.02.2022 • NewsCatalent

Catalent Expands China Clinical Capabilities

US CDMO Catalent plans to expand its facility in Shanghai, China, doubling capacity for the temperature-controlled storage and distribution of clinical supplies and adding secondary packaging capabilities. The expansion is expected to be completed by the middle of this year.

“We have seen great demand for clinical supply services in China. This expansion will increase both capacity and capabilities at the Shanghai facility, and makes provision for the growing trend in clinical trials of advanced therapeutics requiring specialized storage and handling capabilities, including deep-frozen for emerging biotech companies,” said Roel de Nobel, vice president and general manager, APAC, clinical supply services.

The facility in the Waigaoqiao Free Trade Zone is one of two clinical supply sites that Catalent operates in Shanghai – the other, which opened in April 2019, is located in Tangzhen. Together, said Catalent, they provide sponsors with optimized supply solutions for studies performed both in China and Asia-Pacific, as well as worldwide.

Author: Elaine Burridge, Freelance Journalist

(c) Denys Nevozhai
(c) Denys Nevozhai

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.